Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells

Cancer Science

Volumn 105, Issue 8, 2014, Pages 1063-1070

  Wang, Fei ^a   Zhang, Wei ^a   Guo, Liting ^a   Bao, Wen ^a   Jin, Nan ^a   Liu, Ran ^a   Liu, Ping ^a   Wang, Yonghui ^a   Guo, Qinglong ^b   Chen, Baoan ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Gambogic acid; Hypoxia inducible factor 1 alpha subunit; Multiple myeloma; Vascular endothelial growth factor A

Indexed keywords

GAMBOGIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL HYPOXIA; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANGIOGENESIS; GAMBOGIC ACID; HYPOXIA-INDUCIBLE FACTOR 1 ALPHA SUBUNIT; MULTIPLE MYELOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906937492     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12458     Document Type: Article

References (36)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-60.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. Vacca A, Ria R, Reale A et al. Angiogenesis in multiple myeloma. Chem Immunol Allergy 2014; 99: 180-96.
4. Bhutani M, Turkbey B, Tan E et al. Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial. Leukemia 2014; 28: 413-6.
5. Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 2011; 102: 1253-6.
6. Hideshima T, Mitsiades C, Tonon G et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-98.
7. Martin SK, Diamond P, Gronthos S et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533-42.
8. Huang J, Yao X, Zhang J et al. Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci 2013; 104: 1609-17.
9. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-34.
10. Colla S, Storti P, Donofrio G et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010; 24: 1967-70.
11. Azab AK, Hu J, Quang P et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012; 119: 5782-94.
12. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
13. Dai T, Zheng H, Fu GS. Hypoxia confers protection against apoptosis via the PI3K/Akt pathway in endothelial progenitor cells. Acta Pharmacol Sin 2008; 29: 1425-31.
14. Hong SW, Jung KH, Lee HS et al. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Cancer Sci 2012; 103: 1929-37.
15. Mirzoeva S, Kim ND, Chiu K et al. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 2008; 47: 686-700.
16. Kim DH, Hossain MA, Kim MY et al. A novel resveratrol analogue, HS-1793, inhibits hypoxia-induced HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Int J Oncol 2013; 43: 1915-24.
17. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
18. Karar J, Cerniglia GJ, Lindsten T et al. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther 2012; 13: 1102-11.
19. Yang LJ, Chen Y. New targets for the antitumor activity of gambogic acid in hematologic malignancies. Acta Pharmacol Sin 2013; 34: 191-8.
20. Lu N, Hui H, Yang H et al. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1alpha pathway. Eur J Pharm Sci 2013; 49: 220-6.
21. Zhang W, Chen BA, Jin JF et al. Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. Leuk Lymphoma 2013; 54: 2506-16.
22. Ghosh AK, Shanafelt TD, Cimmino A et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009; 113: 5568-74.
23. Minoia C, Quero C, Asselti M et al. Changes in angiogenesis and hypoxia-inducible factor-1alpha protein expression in relapsed/refractory indolent non-Hodgkin lymphomas. Br J Haematol 2013; 163: 640-5.
24. Passam FH, Alexandrakis MG, Kafousi M et al. Histological expression of angiogenic factors: VEGF, PDGFR alpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009; 205: 11-20.
25. Bhaskar A, Gupta R, Vishnubhatla S et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2013; 54: 1473-8.
26. Ria R, Catacchio I, Berardi S et al. HIF-1 alpha of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res 2014; 20: 847-58.
27. Storti P, Bolzoni M, Donofrio G et al. Hypoxia-inducible factor (HIF)-1 alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013; 27: 1697-706.
28. Wang X, Chen W. Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem 2012; 12: 994-1000.
29. Wang Y, Xiang W, Wang M et al. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br J Pharmacol 2014; 171: 618-35.
30. Mazure NM, Chen EY, Laderoute KR et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322-31.
31. Chen EY, Mazure NM, Cooper JA et al. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001; 61: 2429-33.
32. Argyriou P, Papageorgiou SG, Panteleon V et al. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1->HIF-1alpha pathway. Ann Hematol 2011; 90: 315-22.
33. Greijer AE, Delis-Van Diemen PM, Fijneman RJ et al. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch 2008; 452: 535-44.
34. Pore N, Jiang Z, Shu HK et al. Akt1 activation can augment hypoxia-inducible factor-1 alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4: 471-9.
35. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-7.
36. Lang SA, Gaumann A, Koehl GE et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007; 120: 1803-10.